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Abstract. – OBJECTIVE: Frontal sinus sur-
gery has an increased rate of re-stenosis, if 
compared to other sinuses. It depends mainly 
on recurrent inflammation and abnormal scar-
ring at the frontal recess and its reduction rep-
resents one of the keys to therapeutic success. 
Balloon catheter dilation (BCD) and implantable 
sinus stents/spacers represent strategies to im-
prove sinus ventilation respecting the integrity 
of mucosa and reducing abnormal post-surgical 
scarring. The purpose of this study was to evalu-
ate the effectiveness, safety and correct indica-
tion about the use of BCD and a non-absorbable 
stent (Relieva Stratus™ MicroFlow spacer) in the 
management of chronic rhinosinusitis (CRS) of 
the frontal sinus. 
PATIENTS AND METHODS: In this multi-
centric retrospective study we included a pop-
ulation of 76 frontal sinuses with non-polypoid 
CRS. 41 frontal sinuses were treated with BCD 
alone and 35 frontal sinuses with BCD + Spac-
er. We analyzed both radiological (Lund-McKay 
CT scoring modified by Zinreich) and symptom-
atological results (SNOT-20 questionnaire) be-
fore surgery and after 12 months, dividing our 
population in two main groups: group “L” (light/
mild frontal CRS) and group “S” (moderate/se-
vere frontal CRS).
RESULTS: Our results confirm a good safety 
and effectiveness of BCD in the management of 
frontal CRS and show a good safety but a not 
significative effectiveness of Relieva Stratus™ 
MicroFlow spacer when added to BCD in the 
management of light and severe frontal chron-
ic rhinosinusitis. 
CONCLUSIONS: BCD is an acclared option in 
the management of frontal CRS and in the near 
future, utilization of stents/spacers could be-
come a new and effective weapon in the man-
agement of rhinosinusitis, both like an adjunct 
to standard therapies, and in patient popula-
tions where the use of systemic drugs is contra-
indicated. 
Key Words:
Chronic Rhinosinusitis, Sinusitis, Frontal sinus, Endo-
scopic sinus surgery, Balloon catheter dilation, Spac-
er, Stent.
Introduction
Chronic rhinosinusitis (CRS) is a condition of 
chronic inflammation of the mucosal lining of the 
nasal cavity and paranasal sinuses1. Multiple fac-
tors have been implicated in the development of 
CRS, including environmental (bacteria, biofilms, 
fungi and allergens described as factors that lead to 
inflammation of the mucosa of nose and paranasal 
cavities) and host factors (such as immunodeficien-
cy and eicosanoid dysregulation that contribute to 
refractory infections or inflammation) and both 
have a significant impact on the severity of CRS2-4.
Infectious factors (bacterial, including biofilm, 
viral and fungal) indeed coexist with allergic and 
inflammatory factors (affecting the mucosa and the 
underlying bone) and mucociliary clearance defi-
ciency5,6. Endoscopic Sinus Surgery (ESS) is wide-
spread in treating CRS7 and several studies have 
shown that it is an effective and safe treatment for 
patients with CRS when drug therapy has failed8,9. 
The main goal of ESS is to restore the ventilation 
of the diseased paranasal sinuses creating an open 
and accessible cavity, which has been demonstrat-
ed to optimize sinonasal penetration of topical 
medical therapy10. However, ESS for the frontal 
sinus has been shown to have a lower success rate 
compared to other sinuses11,12 and it depends both 
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on perioperative (i.e. extension of frontal sinuso-
tomy) and postoperative (medical management of 
the frontal recess) conditions13. Reasons for failure 
of ESS in frontal sinus include persistent or recur-
rent inflammation and abnormal scarring at the 
frontal recess, leading to restenosis and occlusion 
of the frontal sinusotomy, leading to a high long-
term revision rates (10% to 20% of patients), inde-
pendently of the approach13-18. So, CRS of the fron-
tal sinus is a challenging, constantly evolving and 
extremely controversial condition and the success 
of surgery is, in part, dependent on optimization 
of the postoperative wound-healing process19,20. An 
important goal in the early postoperative period is 
to minimize mucosal inflammation and promote 
normal ciliary function in order to reduce the risk 
of complications such as synechiae formation and 
infection. To minimize postoperative mucosal in-
flammation, most experts would recommend high 
volume saline irrigations and early topical corti-
costeroid therapy21,22; however, the early postop-
erative formation of sinonasal crusting, retained 
secretions, and mucosal edema significantly alter 
the adequate delivery of topical corticosteroid ther-
apy immediately following ESS. Simultaneously, 
in last years, implantable sinus stents/spacers have 
been progressively used following ESS to maintain 
patency of the sinuses and deliver local steroids and 
there has been a recent interest in use of steroid-im-
pregnated spacers for its potential anti-inflamma-
tory properties during the postoperative period23-27. 
Absorbable or non-absorbable sinus stents allow 
a sustained, localized, controlled release of medi-
cation (corticosteroids or saline solution) and can 
be used in conjunction to ESS or Balloon Catheter 
Dilation (BCD) to enable better sinus drainage and 
wound healing. These drug-eluting devices release 
drug-loads slowly and continuously to affected ar-
eas in the sinuses or nasal cavities for a prolonged 
period of time. The purpose of this study was to 
evaluate the effectiveness, safety and correct in-
dication about use of BCD and a non-absorbable 
stent (Relieva Stratus™ MicroFlow spacer) in treat-
ment of CRS of the frontal sinus, trying to evaluate 
the role that these devices could play in the man-
agement of pathology of frontal recess.
Patients and Methods
Patients
We realized a multicentric (Policlinico Um-
berto I, Rome; Bassini Hospital, Milan; Niguar-
da Hospital, Milan) retrospective study to assess 
the validity and safety of BCD vs. BCD with 
utilization of MicroFlow Spacer in symptom-
atological CRS of the frontal sinus. The Ethics 
Committee approval was granted by our Hospi-
tal (Policlinico Umberto I, Rome, Italy). We in-
vestigated a population of 54 adult patients (31 
men and 23 women; overall 76 frontal sinuses 
studied) with non-polypoid CRS (according to 
the criteria defined by the European Position Pa-
per on Rhinosinusitis and nasal Polyps Group. 
2012). 33 patients had been treated with BCD 
alone for a total of 41 frontal sinuses treated (B 
group) and 31 patients had been treated with 
BCD + Spacer for a total of 35 frontal sinuses 
treated (S group). The patients had been subject-
ed to surgery in the 3 different facilities between 
2010 and 2016 for BCD and between 2010 and 
2013 for BCD + Spacer. At the time of surgery, 
patients were aged between 19 and 58 years 
(mean age = 46 years). By medical records we 
obtained medical history data, otorhinolaryngo-
logic examination, the preoperative and postop-
erative SNOT-20 subjective symptomatological 
test28, the preoperative and postoperative endo-
scopic examination of nasal cavity and preoper-
ative and postoperative Computed Tomography 
(CT) in axial, coronal and sagittal planes of pa-
ranasal sinuses. The degree of every frontal si-
nus involvement at CT was evaluated using the 
Lund-MacKay score system modified by Zin-
reich29 (Table I). For a better evaluation of the 
disease, in our study we decided to analyze both 
radiological (modified Lund-McKay CT scor-
ing) and symptomatological results (SNOT-20 
questionnaire) because, although CT scoring are 
objective metrics30, often they do not correlate 
well with rhinologic symptoms31. By protocol, 
all patients had been subjected to standard medi-
cal therapy (antibiotics, corticosteroids and nasal 
irrigations with saline solution) for at least two 
months, in accordance with EPOS guidelines, 
and had not shown improved evaluation crite-
ria. At the end of this period of therapy, they had 
been thus referred to surgery. Exclusion criteria 
had been: pregnancy, revision surgery, CRS with 
nasal polyps, cystic fibrosis, paranasal sinus tu-
mors, allergy to non steroidal anti-inflammato-
ry drugs, coagulopathy, use of anticoagulants, 
osteoneogenesis or Paget’s disease, a previous 
glaucoma diagnosis, uncontrolled hypertension, 
diabetes mellitus, history of facial trauma with 
distorted sinus anatomy. Informed consent had 
been obtained prior to surgery from designated 
staff. Studying pre-operative TC and a SNOT-20 
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questionnaire of every patient, we divided our 
population in two main groups using the modi-
fied Lund-MacKay score system:
 – group “L” (light) included all patients with 
a light/mild involvement of the frontal sinus 
(appreciated with a lower score (1-2) of Zinre-
ich classification) (25 patients/43 pathological 
frontal sinuses);
 – group “S” (severe) included all patients with 
a moderate/severe involvement of the frontal 
sinus (appreciated with an higher score (3-4-
5) of Zinreich classification) (29 patients/33 
pathological frontal sinuses). Patients of the 
“L” group were further divided creating two 
subgroups:
 – LB, in which frontal sinus dilatation with 
BCD had been performed (composed of 24 
frontal sinuses);
 – LS, in which frontal sinus dilation with BCD 
and positioning of MicroFlow Spacer had 
been performed (composed of 19 frontal si-
nuses).
The same division was realized for patients of 
the “S” group, creating the subgroups:
 – SB, in which frontal sinus dilatation with 
BCD had been performed (composed of 17 
frontal sinuses);
 – SS, in which frontal sinus dilation with BCD 
and positioning of MicroFlow Spacer had 
been performed (composed of 16 frontal si-
nuses).
There was homogeneity in primary outcome 
measures (SNOT-20 and Lund-Mackay) between 
the groups. During every procedure, executed un-
der general anesthesia, ESS had been performed 
for each individual case according to the surgical 
need of the patient. So, septoplasty and/or partial 
middle turbinectomy had been performed to in-
crease access to the frontal sinus outflow. All pa-
tients had been treated with a 5x16 mm Relieva* 
sinus catheter (Acclarent), inflated at 10-14 atmo-
sphere for 10 s. At discretion of the surgeon, serial 
balloon dilations had been performed if needed 
to ensure that the frontal sinus outflow tract was 
completely dilated in its entire length. A 30° and 
45° endoscope had been then used to inspect the 
frontal recess and confirm successful dilation. 
After this procedure, patients of the S group had 
been also treated with positioning of Relieva 
Stratus™ MicroFlow spacer (filled with the ste-
roid triamcinolone acetonide 40 mg/ml), removed 
about 4 weeks after in the office setting. In both 
groups, standard postoperative therapy was ad-
ministered, which comprised antibiotics, nasal 
irrigations and topical steroids for 1 month. Stan-
dardized post-surgical management consisted of 
nasal endoscopy and aspiration for removal of se-
cretions and scabs after one week, two weeks, one 
month, 3 months, 6 and 12 months following sur-
gery, using direct visualization with a 30° and 70° 
endoscope to confirm patency of the frontal sinus 
ostia. A 2-mm outer diameter curved suction was 
also passed into the frontal sinus ostia to confirm 
patency. If there was edema, the 2-mm-diameter 
suction was not pushed through the edema but the 
patency of the frontal sinus ostium was measured. 
If edema was fully obstructing the ostium, this 
was recorded as not patent. The permeability of 
frontal recess was defined as a dichotomous vari-
able (yes/no) before surgery and 12 months after 
surgery. The goal of the procedure was the com-
plete resolution of frontal sinus disease shown on 
CT scan after one year follow-up and a consid-
erable improvement of symptoms evaluated with 
SNOT-20 test. The follow-up had been rationally 
planned at one year from surgery because some 
researches32 have shown that a restenosis of the 
frontal sinus occurs usually within 12 months, 
and effectively, after that time, the frontal sinus 
achieves a good re-epithelization, with a very low 
risk of new stenosis and thus a quite certain prob-
ability of permanent results. Twelve months after 
surgery, nasal symptoms were reassessed with 
SNOT-20 questionnaire and a new tomograph-
ic scan was performed to evaluate the degree of 
disease according to the CT Lund-Mackay stage 
system modified by Zinreich, specifically applied 
to the frontal sinus29.
Statistical Analysis
Statistical analysis was realized with Statisti-
ca 10 (Satsoft). Statistical analysis was performed 
with ANOVA for repeated measures by compar-
ing baseline and post-treatment values in the two 
groups of patients. The post-hoc test was done 
with the Newman-Keuls test; p-value < 0.05 was 
considered statistically significant. The interac-
tion between treatments and time was evaluated 
to compare the effectiveness of the two treatments 
in the groups.
Results
Group LB comprised 24 frontal sinuses treat-
ed with BCD and presented a preoperative mean 
SNOT-20 of 62.86 and a mean Lund-MacKay fron-
tal sinus CT preoperative grading modified accord-
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ing to Zinreich of 1.76. Group LS comprised 19 
frontal sinuses treated with BCD + Spacer and pre-
sented a preoperative mean SNOT-20 of 64.21; the 
mean Lund-MacKay frontal sinus CT preoperative 
grading modified according to Zinreich was 1.69. 
The statistical comparison between the two groups 
did not show significant differences in terms 
of SNOT-20 (p=0.711) or radiological grading 
(p=0.713). Group SB comprised 17 frontal sinus-
es treated with BCD and presented a preoperative 
mean SNOT-20 of 68.25 and a mean Lund-MacK-
ay frontal sinus CT preoperative grading modified 
according to Zinreich of 3.42. Group SS comprised 
16 frontal sinuses treated with BCD + Spacer and 
presented a preoperative mean SNOT-20 of 69.16; 
the mean Lund-MacKay frontal sinus CT preoper-
ative grading modified according to Zinreich was 
3.27. Even here the statistical comparison between 
the two groups did not show significant differences 
in terms of SNOT-20 (p=0.79) or radiological grad-
ing (p=0.37).
Postoperative data at 12 months showed these 
results:
 – in subgroup LB (BCD in light sinusitis) 
the mean SNOT-20 decreased from 62.86 
to 22.65 while the mean Lund-Mackay CT 
score in frontal sinuses decreased from 1.76 
to 0.53. No patients were lost at the 12-month 
follow-up and 22 frontal sinuses out of 24 
seemed patent at one-year endoscopic evalu-
ation (91.7%).
 – in subgroup LS (BCD + Spacer in light sinus-
itis) the mean SNOT-20 decreased from 64.21 
to 24.11 while the mean Lund-Mackay CT 
score in frontal sinuses decreased from 1.69 
to 0.61. No patients were lost at the 12-month 
follow-up and 17 frontal sinuses out of 19 
seemed patent at one-year endoscopic evalu-
ation (89.5%).
 – in subgroup SB (BCD in severe sinusitis) 
the mean SNOT-20 decreased from 68.25 
to 23.86 while the mean Lund-Mackay CT 
score in frontal sinuses decreased from 3.42 
to 0.67. No patients were lost as the 12-month 
follow-up and 15 frontal sinuses out of 17 
seemed patent at one-year endoscopic evalu-
ation (88.2%).
 – in subgroup SS (BCD + Spacer in severe si-
nusitis) the mean SNOT-20 decreased from 
69.16 to 25.02 while the mean Lund-Mack-
ay CT score in frontal sinuses decreased 
from 3.27 to 0.73. No patients were lost as 
the 12-month follow-up and 14 frontal si-
nuses out of 16 seemed patent at one-year 
Figure 1. CT score between Balloon Catheter Dilation and MicroFlow Spacer; vertical bars denote 0.95 confidence intervals.
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endoscopic evaluation (87.5%). The preoper-
ative and postoperative score of Lund-Mack-
ay CT score in LB and SB groups demon-
strated a significant reduction (p=0.00012 
and p=0.00015), the same happened for LS 
and SS groups (p=0.00012 and p=0.00015) 
(Figure 1). Comparison between the two 
techniques was not significant both in light 
sinusitis (p=0.624) and in severe sinusitis 
(p=0.574). Comparing preoperative and post-
operative SNOT-20 score in patients treated 
with BCD in both light and severe sinusitis 
(LB - SB), we found that there was a signif-
icant reduction (p=0.00012 and p=0.00015). 
We found the same result in patients treated 
with BCD + Spacer (LS - SS) (p=0.00012 
and p=0.00012) (Figure 2). The comparison 
between the two techniques for light sinus-
itis (LB vs. LS) was not significant (p=0.750). 
The same resulted between the two tech-
niques in patients with severe sinusitis (SB 
vs. SS) (p=0.792). No major complications 
were observed in either group, although mi-
nor epistaxis was reported occasionally. The 
cases of frontal recess obstructed following 
treatment with BCD or BCD + Spacer were 
subjected to revision surgery. None of our 
patients developed complications as a result 
of the BCD procedure or Spacer positioning 
procedure including orbital or skull base de-
hiscence and mucocele formation.
Discussion
Failures in frontal CRS surgery are more fre-
quent than in other sinuses CRS surgery and they 
can often be prevented with a correct and focused 
post-surgical therapeutic management. Mucosal 
and bony tissue reactivity play a pivotal role in ex-
acerbating CRS33,34; therefore, for the long-term re-
duction of mucosal inflammation, it represents one 
of the keys for obtaining a therapeutic success.
In 2005, the United States Food and Drug Ad-
ministration (FDA) approved BCD for diagnostic 
and therapeutic approaches to the paranasal sinus-
es. BCD consists of a high-pressure compression of 
the sinus mucosa with a balloon that creates mi-
crofractures in the bone surrounding the sinus os-
tium and his outflow tract to improve sinus drain-
Figure 2. SNOT-20 comparison between Balloon Catheter Dilation and MicroFlow Spacer; vertical bars denote 0.95 confi-
dence intervals.
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age and ventilation, respecting the integrity of 
mucosa. It represents a minimally invasive proce-
dure that aims to restore physiological sinus drain-
age preventing abnormal scarring associated with 
mucosal stripping35,36. BCD can be performed 
alone or in conjunction with traditional ESS. Cur-
rently, there are four companies with FDA-cleared 
balloon dilation systems: Acclarent* (Menlo Park, 
CA, USA), Entellus Medical* (Plymouth, Minne-
sota, USA), Ventera* (Reston, VA, USA), and 
Medtronic* (Dublin, Ireland). The rationale behind 
the use of BCD in frontal sinus involves the ability 
of this technique to microfracturing and remodel-
ing the bone in frontal recess, preserving the integ-
rity of surrounding mucosa. In this way, the combi-
nation of this improved bony and mucosal patency, 
could be sufficient to restore the sinus continued 
physiological drainage and ventilation. In addic-
tion, even in case of surgical failure the frontal si-
nus remains available to further surgical interven-
tion (re-dilation or advanced endoscopic traditional 
surgery). A recent important review37 on the use of 
balloon procedure in rhinosinusitis suggests a ben-
efit in certain circumstances for BCD of the frontal 
sinus when applied as either a stand-alone or hy-
brid procedure. The same research concludes that 
findings are not sufficient to reach consensus in 
relation to the outcomes of BCD in different sever-
ity levels of CRS as graded by CT, and other stud-
ies with appropriate controls (comprehensive pre-
operative assessments, including CT scan severity) 
are needed to establish the different outcomes that 
this technique can achieve in light and severe rhi-
nosinusitis. In a previous trial, we compared the 
safety and efficacy of BCD with traditional ESS 
demonstrating the substantial similarity between 
these two techniques that must be alternative weap-
ons of this kind of surgery [38]; we divided the 
population affected in two groups, one with light/
mild frontal CRS and the other with moderate/se-
vere frontal CRS (basing on radiological findings 
at Lund-MacKay modified by Zinreich score). Our 
data showed a better improvement at SNOT-20 
questionnaire in patients with severe rhinosinusitis 
that underwent BCD compared to traditional ESS. 
The standard treatment of CRS is local and sys-
temic drug therapy and there is increasing evidence 
of the favorable effect of topically administered 
glucocorticoid therapy on inflammatory character 
of CRS. The topical administration of steroids is 
safe and may have only minor side effects, such as 
mucosal irritation, crusting and minor nose bleed-
ings. The main problem in drug delivery to the af-
fected paranasal sinus mucosa is the complexity of 
the sinus anatomy, especially in the frontal re-
cess39,40. Topical steroids are widely used postoper-
atively as they can facilitate early mucosalization 
and reduce edema, granulation tissue formation 
and fibrin deposition20. However, many investiga-
tions41-44 have reported that topical nasal steroid 
sprays do not reach adequately the frontal recess 
and hence are quite effective in post-surgical man-
agement of patients with frontal sinusitis; so, the 
challenge of topical steroid therapy remains ade-
quate drug delivery and patient compliance. On the 
other hand, oral steroids, although effective in 
treating the inflammatory response, have shown a 
higher rate of systemic risks for the patient and, 
therefore, are prescribed with caution45,46. The dif-
ferences of local distribution of drug between nasal 
drug-eluting implants and standard nasal sprays 
are summarized in Figure 324. As observed, little 
quantity of drug are detected within a few hours 
using nasal sprays, while drug-eluting nasal im-
Figure 3. Comparison of the plots of nasal drug concen-
tration versus time, obtained after administration of nasal 
sprays and drug-eluting implants. Nasal sprays show rapid 
clearance of the drug from the nasal mucosa as compared to 
locally acting implants.
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plants ensure a continuous and prolonged drug re-
lease to the affected mucosa for CRS treatment. 
Another important problem is that preventing post-
operative complications is not only an important 
quality-of-care outcome for patients, but it also re-
duces potentially wasted economic resources used 
by the interventions required to solve the complica-
tions47,48. For this reason, policy makers and third 
party players well recognize the importance of pre-
vention of complications and avoidance of revision 
surgery; so, they place value on interventions that 
achieve this endpoint. Therefore, it is important to 
identify management strategies aimed to reduce 
the total duration of systemic corticosteroid thera-
pies and to improve the delivery of topical steroids 
in frontal sinus. At this regard, the use of ste-
roid-eluting stent or spacers may represent a novel 
strategy to reach this goal. In last years, a variety of 
devices have been tested in the paranasal sinuses 
after endoscopic sinus surgery with varying suc-
cess; these include packing materials, injectable 
space-filling gels or structured stents. Sinus stents 
may be composed of non-absorbable alloplastic 
materials (i.e. silicone, plastic) that must be re-
moved in the office setting after a variable period 
of time or absorbable biomaterials (i.e. bovine gel-
atin, poly(lactic-co-glycolic acid)), that degrade 
spontaneously and gradually in a controlled time 
following surgery. Sinus stents are also defined 
“spacers” because they maintain separation be-
tween critical areas of healing to prevent edema, 
scar formation and restenosis. Incorporation of a 
drug such as corticosteroids, antibiotics or an-
ti-neoplastic agents into these nasal devices is the 
primary and most interesting focus of developing 
drug-eluting nasal implants49. Drug-eluting sinus 
implants can be used very effectively after sinus 
surgery because of their ability to maintain sinus 
patency by providing controlled, constant drug re-
lease over a variable period of time to the surround-
ing sinus mucosa50. Examples of clinically ap-
proved implants include Propel™ implant, Relieva 
Stratus™ MicroFlow spacer and the Sinu-Foam™ 
spacer. Due to its position as an emerging technol-
ogy, the role of steroid-eluting stents in the man-
agement of surgical CRS patients has yet to be ful-
ly assessed; data reported in literature show 
significant variability in the outcomes of these im-
plants designed and aimed to maintain sinus paten-
cy and drug releasing to the affected sinus muco-
sa51. An assessment52 by the National Institute for 
Health and Care Excellence (NICE, 2016) con-
cludes: “Current evidence on the safety of cortico-
steroid-eluting bioabsorbable stent or spacer inser-
tion during endoscopic sinus surgery to treat 
chronic rhinosinusitis raises no major safety con-
cerns…NICE encourages further research on cor-
ticosteroid-eluting bioabsorbable stent or spacer 
insertion during endoscopic sinus surgery and, 
specifically, controlled studies designed for be-
tween-patient (rather than within-patient) compari-
sons. Outcomes should include symptom scores, 
quality of life and the need for retreatment in the 
long-term. All complications should be reported”. 
In a Cochrane review published in 2015, Huang et 
al23 evaluated the safety and effectiveness of ste-
roid-eluting sinus stents placement in CRS patients 
after ESS, but they concluded that there was cur-
rently no evidence to demonstrate the benefits of 
steroid-eluting sinus stents when compared to 
non-steroid-eluting sinus stents, nasal packing or 
no treatment. Similarly, there was no evidence to 
show that one steroid-eluting sinus stent was supe-
rior to another. In another trial using an intra-pa-
Table I. Zinreich Staging System (Modification of Lund-Mackay).
Zinreich staging system.
Zinreich Staging System (Modification of Lund-Mackay)
Scores Each Sinus 0-5, OMC 0-2
0 = 0%, 1 = 1-25%, 2 = 26-50%, 3 = 51-75%, 4 = 76-99%, 5 =100%
Right Left
Maxillary Maxillary
Anterior ethmoid Anterior ethmoid
Posterior ethmoid Posterior ethmoid
Sphenoid Sphenoid
Frontal Frontal
Osteomeatal complex Osteomeatal complex
Total (maximum = 54)
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tient control design, Smith et al53 evaluated the 
safety and effectiveness of a steroid-eluting im-
plant in improving surgical outcomes when placed 
in the frontal sinus following ESS in patients with 
CRS; the authors demonstrated the effectiveness of 
steroid-eluting implants in improving outcomes of 
frontal sinus surgery. The Relieva Stratus™ Micro-
Flow spacer from Acclarent* (Menlo Park, CA, 
USA) is a temporarily implanted drug-eluting stent 
designed to provide slow release of steroids into 
frontal or ethmoid sinuses over a 2-4 week period 
with the intention of maintaining sinus ostial pa-
tency. It was introduced in 2009 as a minimally 
invasive surgical tool to treat chronic ethmoidal 
and frontal sinusitis. In the United States, the FDA 
approved the spacer loaded only with sterile saline, 
while in Europe, the device received a CE Mark 
approval for the use of triamcinolone acetonide (40 
mg/ml), asserting that the mechanism of action 
would have been topical, so no significant systemic 
effects would have been expected. The implanta-
tion of this device is quick, simple and safe to per-
form and the complication rate ought to be very 
low basing on previous literature54, 55 even if one 
orbital complication has been reported in the liter-
ature. The device was then easily removed in the 
office setting. Catalano et al57 tried to evaluate the 
safety and short-term outcomes of this device in 
ethmoid sinus and they concluded that this spacer 
appeared safe and effective in treating chronic eth-
moid sinus disease within the defined follow-up 
period of 6 months. Taulu et al58 compared the op-
tical Image-Guided Surgery (IGS)-assisted inser-
tion of the device with fluoroscopic insertion and 
concluded that, from a technical perspective, 
IGS-guided insertion was a faster, safer and more 
exact procedure that guaranteed the optimal posi-
tioning and effectiveness of the implant. Businco et 
al59 evaluated the safety and effectiveness of this 
device in the management of allergic CRS in com-
parison with the traditional endoscopic ethmoidec-
tomy and concluded that in their experience, the 
use of this spacer was effective in treatment of al-
lergic patients with ethmoidal CRS when conven-
tional medical treatment had failed, or when wish-
ing to avoid the traditional ESS. Anyway, in May 
2013, Acclarent voluntarily discontinued all sales 
of the Stratus device and withdrew all approved 
FDA clearances, making the devices no longer 
available for sale in the United States.
The major disadvantage of Relieva Stratus™ 
MicroFlow spacer was its duration of use (14-28 
days). Probably, this was not sufficient to treat 
chronic inflammation of CRS, which lasts for 
more than 12 weeks7 and thus a relapse of infec-
tion/inflammation can ensue. This statement is 
coherent and can probably explain our results, 
in which it is showed a not statistically signif-
icant difference at one year-control between 
treatment with BCD and treatment with BCD + 
spacer in the frontal sinus, both in patients with 
light/mild frontal CRS (p>0.05) and in patients 
with moderate/severe frontal CRS (p>0.05), 
studied with Lund-Mackay modified by Zinre-
ich score. The same not statistically significant 
difference was observed comparing the results 
of SNOT-20 questionnaire at one year-control 
between treatment with BCD and treatment 
with BCD + spacer in the frontal sinus, both in 
patients with light/mild frontal CRS (p>0.05), 
and in patients with moderate/severe frontal 
CRS (p>0.05). Anyway, not significant adverse 
events were encountered in our study.
Conclusions
Our findings confirm the good safety and ef-
fectiveness of BCD in the management of light 
and severe frontal CRS and show a good safety 
but not significant effectiveness of Relieva Stra-
tus™ MicroFlow spacer when added to BCD in 
the management of light and severe frontal CRS. 
Nevertheless, in this trial we evaluated the safety 
and efficacy of a kind of nasal stent, but additional 
studies are needed to demonstrate the safety and 
efficacy of every kind of implant. We suggest a 
further development of devices releasing drugs, 
probably improved in time of permanence and re-
absorption in the affected site and perhaps with the 
possibility to distribute several drugs in synergic 
association. These devices could become another 
option in the management of rhino-sinusitis, both 
like an alternative to standard therapies, and in pa-
tient populations where the use of systemic drugs 
can be contraindicated, like patients with immuno-
deficiency, diabetes mellitus, uncontrolled hyper-
tension, serious osteoporosis or other conditions in 
which the surgeon wants to avoid the oral steroids 
administration to the patient. Moreover, evaluating 
the cost-effectiveness of the steroid-eluting im-
plants compared to other interventions for manag-
ing complications (i.e. surgery revision) should be 
the focus of future economic evaluations.
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